# Vitro Biopharma, Inc.

Vitro Biopharma, Inc. is a company headquartered in Denver, CO, United States.

## Company overview

- **Legal name:** Vitro Biopharma, Inc.
- **Former names in filing history:** VITRO DIAGNOSTICS INC (1996-12-13 to 2021-10-20)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Denver, CO, United States
- **Incorporated in:** NV
- **Fiscal year end:** October 31
- **SEC CIK:** 0000793171

## About

Vitro Biopharma, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000793171, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2026-02-13, it reported annual revenue of USD 2,056,818; net income of USD -10,851,802; total assets of USD 4,929,210 for the fiscal period ended 2025-10-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-10-31)

- **Revenue:** $2.1M (USD 2,056,818)
- **Net income:** -$10.9M (USD -10,851,802)
- **Total assets:** $4.9M (USD 4,929,210)
- **Operating cash flow:** -$2.5M (USD -2,537,843)

### FY2024 (period ended 2024-10-31)

- **Revenue:** $1.9M (USD 1,855,644)
- **Net income:** -$9.9M (USD -9,873,560)
- **Total assets:** $5.1M (USD 5,089,047)
- **Operating cash flow:** -$3.2M (USD -3,236,339)
- **Later filings:** Total assets: shown as originally filed; later filings report different values for the same periods.

### FY2023 (period ended 2023-10-31)

- **Revenue:** $1.8M (USD 1,763,451)
- **Net income:** -$5.4M (USD -5,356,717)
- **Total assets:** $8.3M (USD 8,343,534)
- **Operating cash flow:** -$2.0M (USD -1,968,835)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2015 (period ended 2015-10-31)

- **Revenue:** $77,801 (USD 77,801)
- **Net income:** -$245,865 (USD -245,865)
- **Total assets:** $116,099 (USD 116,099)
- **Cash and equivalents:** $5,272 (USD 5,272)
- **Operating cash flow:** -$100,403 (USD -100,403)

## Recent SEC filings

- Form 10-Q — filed 2026-09-18 — period 2026-07-31 — 10-Q
- Form 10-Q — filed 2026-06-15 — period 2026-04-30 — 10-Q
- Form 10-Q — filed 2026-03-16 — period 2026-01-31 — 10-Q
- Form 10-K — filed 2026-02-13 — period 2025-10-31 — 10-K
- Form 10-Q — filed 2025-09-12 — period 2025-07-31 — 10-Q
- Form 10-Q — filed 2025-06-20 — period 2025-04-30 — 10-Q
- Form 10-Q — filed 2025-03-20 — period 2025-01-31
- Form 10-K — filed 2025-01-28 — period 2024-10-31
- Form 10-Q — filed 2024-09-16 — period 2024-07-31
- Form 8-K — filed 2024-07-22 — period 2024-07-16
- Form 8-K — filed 2024-06-27 — period 2024-06-21
- Form 10-Q — filed 2024-05-31 — period 2024-04-30

---

Updated: 2026-10-23T20:12:17Z

Canonical page: https://altss.com/profile/vitro-biopharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology